GAM
LEGN icon

Groupama Asset Management’s Legend Biotech LEGN Stock Holding History

Groupama Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,947
Closed -$1.68M – 413
2025
Q1 		$1.68M Buy
47,947
+3,040
+7% +$109K 0.03% 206
2024
Q4 		$1.47M Buy
44,907
+17,533
+64% +$726K 0.03% 231
2024
Q3 		$1.33M Buy
27,374
+4,592
+20% +$245K 0.03% 219
2024
Q2 		$1.01M Buy
22,782
+1,360
+6% +$62.7K 0.01% 294
2024
Q1 		$1.2M Buy
+21,422
New +$1.29M 0.02% 290

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Groupama Asset Management's LEGN Position: Q2 2025 in Review

Groupama Asset Management sold out of Legend Biotech (LEGN) in Q2 2025, closing a stake of 47,947 shares — an estimated $1.68M sold.

Groupama Asset Management first reported a position in LEGN in Q1 2024 and held it in 5 quarters. The position peaked at $1.68M in Q1 2025. 211 funds tracked by Wall St. Rank hold LEGN as of Q2 2025.

  • Groupama Asset Management reported no remaining Legend Biotech position as of Q2 2025 after selling out during the quarter.
  • Groupama Asset Management sold 47,947 Legend Biotech shares in Q2 2025, an estimated $1.68M.
  • Groupama Asset Management first reported a position in Legend Biotech in Q1 2024 and held it in 5 quarters.
  • Groupama Asset Management's Legend Biotech position peaked at $1.68M in Q1 2025.
  • 211 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2025.

Based on Groupama Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.